Semaglutide doses: what the escalation schedule actually means

The biggest misconception: more dose sooner does not mean more weight loss sooner

Search for semaglutide doses and you will find plenty of posts from people who felt "nothing" at 0.25 mg and wondered whether they had a faulty pen. They didn't. The 0.25 mg starting dose was never designed to produce weight loss. Its job is to let your gut adjust to the medicine before the doses that actually shift the needle. Pushing to a higher step before your body has settled almost always means worse nausea, not faster results. The escalation timetable exists because the clinical trials that got Wegovy licensed were built around it.

A related myth: that the maintenance dose is always 2.4 mg. For most people on the injection, 2.4 mg is where the prescriber aims, but some people find a lower step is the highest they tolerate comfortably. Staying at 1.7 mg long-term is a legitimate clinical decision, not a failure. Your prescriber weighs your response and tolerance at each review, that conversation matters more than matching a number you read online.

One quick habit worth building: before each new pen arrives, check the label against your current prescription. Dose mix-ups are rare but they do happen, especially if someone is collecting for a family member or if there has been a recent change. Takes about thirty seconds and removes the guesswork entirely.

The injection dose steps, what changes at each level

The licensed weekly injection schedule runs: 0.25 mg for the first four weeks (the starting dose, purely for tolerability), then 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, and finally 2.4 mg as the standard maintenance target. A prescriber can keep you at any step longer if your side effects need more time to settle.

In January 2026 the MHRA approved 7.2 mg as an additional maintenance dose, initially delivered as three 2.4 mg pens per week, and on 14 April 2026 a dedicated single-dose 7.2 mg pen was approved for adults with a BMI of 30 or above. That higher dose is not available to everyone, the MHRA approval is specifically for obesity (BMI at or above 30), not for the cardiovascular indication, and titration still starts at 0.25 mg. If you want to understand what each Wegovy dose step involves clinically, that page goes into the detail for each level.

Trial data published in the New England Journal of Medicine (the STEP 1 trial, 68 weeks, 2.4 mg) showed an average body-weight reduction of around 15% at the 2.4 mg maintenance dose. The newer 7.2 mg data reports around 20.7% average loss over 72 weeks, approaching the figures seen with tirzepatide at higher doses, though a prescriber will discuss which medicine suits your circumstances.

Oral semaglutide has a completely separate dose ladder

Wegovy tablets (approved by the MHRA on 11 June 2026 as the first oral GLP-1 licensed in the UK for weight management) use a different schedule entirely. The steps are 1.5 mg, 4 mg, 9 mg and 25 mg daily, with at least a month at each level before any increase. The 25 mg tablet is the maintenance dose.

This is where confusion with Rybelsus creeps in. Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes and comes in 3 mg, 7 mg and 14 mg strengths. Those numbers are not rungs on the Wegovy weight-loss ladder. If you have seen references to 3 mg semaglutide or 7 mg semaglutide tablets in a weight-loss context, they are almost certainly describing Rybelsus, which is not licensed for weight management and is not the same product. The 14 mg tablet follows the same pattern, Rybelsus, not Wegovy.

The tablet is taken first thing in the morning, on an empty stomach, with a small amount of plain water. Nothing else (no coffee, no food, no other oral medicines) for at least 30 minutes afterwards. Room-temperature storage means no fridge needed, which some people find more practical than the injection. The trade-off is that the tablet requires a stricter daily routine to work as the trials showed.

What semaglutide doses are available through a private prescription, and how the review works

On the NHS, access to Wegovy runs through specialist weight management services under NICE guidance TA875, and waiting times vary considerably. Private prescriptions follow the same licensed dose schedule but without the referral pathway or the wait, a GPhC-registered Independent Prescriber reviews your consultation, and if the medicine is clinically suitable, treatment is dispensed through a regulated UK pharmacy.

Semaglutide pen doses are not something you choose yourself; each step up is subject to a clinical review. At nume, no dose increase goes through without that review, a real prescriber looks at your progress, not software. You can find more about how that works on the Wegovy overview page, and if cost is a factor in your thinking, a clear comparison of Wegovy pricing in the UK sets out what different providers typically include. Our weight-loss treatment page covers the broader options if you are still weighing up which route suits you.

These are prescription-only medicines and the dose schedule is not a suggestion, it is a clinical structure built from the evidence. If you want to talk through which dose step you should be at, or whether semaglutide is the right medicine for your situation, speaking to one of our prescribers is the straightforward next step.